Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
  • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
  • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/10—Nitrogen as only ring hetero atom
  • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
  • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
  • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

• the present invention relates to improved dosing of medications.
• the present invention relates to improved dosing of a medication whereby two or more effective, time-separated doses may be provided by administration of a single dosage unit. The second, and any later, dose is time-delayed following administration. Based on predictable in vitro release times, the dosage forms can be formulated to deliver delayed doses in vivo at desired times.
• the dosage forms and methods of the present invention are particularly suitable for the administration of methylphenidate hydrochloride, and especially for the administration of a single isomer, d-t/zreo-methylphenidate hydrochloride.
• dosage forms which contain an immediate dosage and a delayed second dosage provides for reduced abuse potential, improved convenience of administration, and better patient compliance, especially when methylphenidate is used to treat certain central nervous system disorders.
• Attention Deficit Disorder a commonly diagnosed nervous system illness in children, is generally treated with methylphenidate hydrochloride (available commercially as, e.g., Ritalin®). Symptoms of ADD include distractibility and impulsivity. A related disorder, termed Attention Deficit Hyperactivity Disorder (ADHD), is further characterized by symptoms of hyperactivity, and is also treated with methylphenidate hydrochloride. Methylphenidate drugs have also been used to treat cognitive decline in patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS related conditions. See, e.g., Brown, G., Intl. J. Psych. Med. 25(1): 21-37 (1995); Holmes et al., J Clin. Psychiatry 50: 5-8 (1989).
• AIDS Acquired Immunodeficiency Syndrome
• Methylphenidate exists as four separate optical isomers as follows:
• R 2 is phenyl.
• Pharmaceutically acceptable salts are generally administered clinically.
• Other phenidate drugs which also can be a dministered according to the invention, include those in which the methyl group in the above structures is replaced by C 2 -C 4 alkyl and R 2 is optionally substituted with C,-C 4 alkyl.
• methylphenidate hydrochloride salt is commonly referred to simply as "methylphenidate".
• methylphenidate is used broadly herein to include methylphenidate and pharmaceutically acceptable salts thereof, including methylphenidate hydrochloride.
• the threo racemate (pair of enantiomers) of methylphenidate is a mild central nervous system stimulant with pharmacological activity qualitatively similar to that of amphetamines.
• Undesirable side effects associated with the use of the dl-threo racemate of methylphenidate include anorexia, weight loss, insomnia, dizziness and dysphoria.
• the racemate which is a Schedule II controlled substance, produces a euphoric effect when administered intravenously or through inhalation or ingestion, and thus carries a high potential for abuse.
• sustained release formulations of dl-threo methylphenidate have been developed, which provide for slow release of the drug over the course of the day. However, it has been observed that peak plasma concentrations of the drug are lower when sustained release formulations are used. In some studies, sustained release formulations of methylphenidate have been shown to have lower efficacy than conventional dosage forms.
• Figure 1 depicts an in vitro time-concentration relationship (release profile) for certain preferred dosage forms in accordance with the invention.
• Figure 2 depicts a schematic representation of in vivo plasma concentration of a drug released according to the release profile shown in Figure 1.
• the present invention provides, in one embodiment, a therapeutic composition for the oral administration of a methylphenidate drug comprising a dosage form containing two groups of particles, each containing the methylphenidate drug.
• the term "particles", as used herein, includes pellets, granules, and the like.
• the first group of particles provides a substantially immediate dose of the methylphenidate drug upon ingestion by a mammal.
• the first group of particles can also comprise a coating and/or sealant.
• the second group of particles comprises coated particles, which comprise from about 2% to about 75%, preferably from about 2.5 % to about 50%, and more preferably from about 5% to about 20%, by weight of the second group of particles, of the methylphenidate drug, in admixture with one or more binders.
• the coating comprises a pharmaceutically acceptable ammonio methacrylate copolymer in an amount sufficient to provide a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose.
• one or more additional doses may be delivered by additional particles, coated in a similar manner, but with a sufficient amount of ammonio methacrylate copolymer coating to provide the dosage after an additional delay.
• Methylphenidate and pharmaceutically acceptable salts thereof, including methylphenidate hydrochloride can be prepared into the dosage forms of the invention.
• the first group of particles comprises a methylphenidate drug and provides a substantially immediate dose of the methylphenidate drug upon ingestion by a mammal.
• the first group of particles may comprise a coating and/or sealant.
• the second group of particles comprises coated particles, which comprise from about 2% to about 75%, preferably from about 2.5% to about 50%), and more preferably from about 5% to about 20 %, by weight of the particles of the methylphenidate drug in admixture with one or more binders.
• the coating comprises a pharmaceutically acceptable ammonio methacrylate copolymer in a quantity sufficient to provide a dose of methylphenidate delayed by from about 2 hours to about 7 hours following ingestion.
• the first group of particles can comprise a pharmaceutically acceptable salt of methylphenidate, such as methylphenidate hydrochloride, in powder form, or coated or uncoated particles containing the methylphenidate salt.
• the amount of methylphenidate salt in each group of particles can vary, depending upon the dosage requirements of the patient to whom the drug is to be administered.
• the daily dosage requirement for methylphenidate drugs is from about 1 mg to about 50 mg per day, preferably from about 2 mg to about 20 mg, and more preferably from about 2.5 to about 12 mg per day.
• the actual dosage to be administered will be determined by the attending physician as a matter of routine.
• the amount of methylphenidate drug can be, for example, from about 2% to about 99% by weight of the first group of particles.
• the second group of particles comprises a filler, such as a hydrophobic filler, one or more ammonio methacrylate copolymers, and optional excipients and other additives.
• the filler can be present in an amount of, for example, from about 35% to about 45%, by weight, based on the total weight of the second group of particles.
• Another embodiment of the present invention provides a method for treating disease, such as, for example, ADD, ADHD, or AIDS-related dementia, in a patient in need of treatment.
• This treatment comprises administering to the patient a dosage form providing once-daily oral administration of a methylphenidate drug such as methylphenidate hydrochloride.
• the dosage form comprises at least two groups of particles, each containing the methylphenidate drug.
• the first group of particles comprises from about 2% to about 99% by weight of the methylphenidate drug, depending upon desired the daily dosage, and provides a substantially immediate dose of methylphenidate upon ingestion by a mammal.
• the first group may comprise a coating and/or sealant.
• the second group of particles comprises coated particles.
• the coated particles comprise the methylphenidate drug in admixture with one or more binders, wherein the amount of methylphenidate drug is from about 2% to about 75%, preferably from about 2.5 % to about 50%, and more preferably from about 5% to about 20 %, by weight of the second group of particles, and a coating comprising an ammonio methacrylate copolymer in a quantity sufficient to provide a dose of methylphenidate delayed by from about 2 hours to about 7 hours following ingestion.
• the components of the two groups of particles can vary as described hereinabove.
• the initial dose can be administered separately from the delayed dose, if desired.
• a further embodiment of the present invention provides dosage forms for the oral administration, in a single dosage form, of two doses of a pharmaceutically acceptable salt of -t/zre ⁇ -methylphenidate.
• the dosage forms comprise particles containing within their interiors from about 2% to about 75%, preferably from about 2.5% to about 50%, and more preferably from about 5% to about 20 %, of the d-threo- methylphenidate salt, in admixture with one or more binders.
• the particles have a coating exterior to the methylphenidate salt, which comprises an ammonio methacrylate copolymer in a quantity sufficient to delay release of the -t/zre ⁇ -methylphenidate salt contained within by from about 2 hours to about 7 hours following administration.
• the dosage forms also comprise, exterior to the coating, an outer layer comprising from about 2% to about 99%) by weight of the d-t/zre ⁇ -methylphenidate salt, based on the weight of all components in the outer layer, to provide a substantially immediate dose of the d-threo- methylphenidate salt upon administration.
• the layer comprising the immediate dose of the ⁇ f-t/zre ⁇ -methylphenidate salt can, if desired, further comprise an outer sealant layer. If desired, the two doses of the -t zreo-methylphenidate salt can be approximately equal.
• the present invention also provides dosage forms providing plasma concentration profiles for methylphenidate having two maxima, temporally separated from each other by from about 2 hours to about 7 hours.
• the magnitude of said maxima differs by no more than about 30 percent, more preferably by no more than about 20 percent, and most preferably by no more than about 10 percent.
• “Methylphenidate” as used herein includes all four optical isomers of the compound and all pharmaceutically acceptable salts thereof. When one or more particular isomers is contemplated, the isomer is indicated, as in d-threo, l-threo, etc. The combined threo isomers may be indicated simply as “threo " and the erythro isomers as "erythro " .
• dl-threo methylphenidate hydrochloride is generally used, while d-threo methylphenidate hydrochloride is preferred according to the present invention.
• the four isomers have exhibited varying levels of therapeutic activity, and have been shown to differ generally in producing unwanted side effects.
• the present invention provides dosage forms which maximize therapeutic effectiveness and minimize undesirable side effects.
• the dosage forms of the present invention provide administration of the two threo forms of methylphenidate.
• the dosage forms of the present invention provide administration of a single isomer, d-t/zreo-methylphenidate, albeit in two or more doses.
• the dosage forms of the present invention are intended for oral ingestion by a mammal, particularly a human.
• the dosage forms of the present invention are particularly suitable for the administration of methylphenidate drugs, in at least two doses.
• the dosage forms provide two doses of a d-th eo methylphenidate drug such as d-threo methylphenidate hydrochloride.
• the second dose can be delayed by from about 2 hours to about 7 hours, preferably from about 3 hours to about 6 hours, and most preferably from about 4 hours to about 5 hours, following ingestion of the dosage form by a mammal.
• Figure 1 is an in vitro drug release profile of a dosage form of the present invention. The data were obtained by measuring the rate of dissolution of drug as a function of time.
• two doses are provided.
• the release of the first dose preferably occurs substantially immediately; for example, within about 30 minutes following administration. Following a period of little or substantially no drug release, the second dose is released.
• the two releases can be referred to as "pulses", and such a release profile can be referred to as "pulsatile”.
• Figure 2 is a schematic representation of the plasma concentration of drug resulting from a release profile according to Figure 1.
• the maximum concentration due to the first dose, C, occurs at t,, preferably from about 1 hour to about 3 hours after ingestion, most preferably about 2 hours after ingestion.
• the release of the first dose is followed by a period during which substantially no drug is released, which lasts approximately 2-6 hours, preferably 3-5 hours, post ingestion.
• the second dose is then released, with the maximum concentration, C 2 , at t 2 , which is preferably about 6 hours post-ingestion.
• Preferably at least about 80% of the total drug has been released by about 6 hours following administration.
• the levels of drug released at the two maxima are nearly equal.
• the release of the two doses provides a plasma concentration profile having two maxima, which differ from each other by no more than about 40 percent in magnitude, preferably by no more than about 30 percent, and more preferably by no more than about 25 percent. This is determined by the relationship:
• the maxima differ by no more than 20%.
• embodiments in which the maxima of the two releases differ by more than 40 percent are within the scope of the invention.
• the appropriate relative amounts of drug in each release can be readily determined by one skilled in the art.
• Dosage forms of the present invention provide controlled release of a methylphenidate drug, including pharmaceutically acceptable salts of methylphenidate, whereby an initial dose for immediate release can be combined with a delayed release of one or more additional doses.
• Such dosage forms may alternatively be referred to as "pulsatile" dosage forms.
• delayed release means release within about a half hour following ingestion, preferably about 15 minutes, and more preferably within about 5 minutes following ingestion.
• Dellayed release refers to a drug release profile which includes a period during which no more than about 10 percent of the drug in a particular dosage form is released, followed by a period of from about 0.5 hour to about 2.5 hours, preferably about 1.5 hours, more preferably about 1 hour, in which no less than about 70 percent, preferably no less than about 80 percent, and more preferably no less than about 90 percent, of the drug is released.
• the terms “medication” and “drug” are used interchangeably herein. According to the present invention, delayed release dosage forms can be combined with forms which provide immediate release of a drug.
• two or more dosage forms can be combined, one dosage form providing a portion of a patient's daily dosage needs of a drug and subsequent dosage forms providing additional portions of a patient's daily dosage needs.
• a drug can be administered to a patient in two dosage forms simultaneously, one providing, e.g., about 30-50 percent of the patient's daily requirement of the drug and the second providing the remainder of the patient's daily requirement.
• a single dosage form can be administered which includes an immediate dose of some portion of a patient's daily requirement and one or more delayed doses to provide the remaining portion or portions of the patient's daily requirement.
• Dosage forms of the present invention provide an initial dose of a drug such as, for example, a pharmaceutically acceptable salt of -t/zre ⁇ -methylphenidate (also referred to herein as d-MPD), followed by an interval wherein substantially no additional drug is released, followed in turn by release of a second dose. If desired, a second substantially release-free interval may be provided following the second release, followed in turn by a third dose.
• a drug such as, for example, a pharmaceutically acceptable salt of -t/zre ⁇ -methylphenidate (also referred to herein as d-MPD)
• a second substantially release-free interval may be provided following the second release, followed in turn by a third dose.
• dosage forms providing 3 or more doses are contemplated by the present invention. However, dosage forms providing 2 or 3 doses are generally preferred for therapeutic use, with 2 doses being more preferred.
• the first dose can provide from about 30 percent to about 70 percent of a patient's daily prescribed intake of the drug and the second dose provides from about 70 percent to about 30 percent.
• the initial dose preferably provides from about 40 percent to about 60 percent
• the second dose preferably provides from about 60 percent to about 40 percent, of a patient's prescribed daily intake of the drug.
• the first dose and the second dose can each provide about 50 percent of a patient's prescribed daily intake of drug.
• the effect of drug metabolism in the body may require adjustment of the relative amounts of each dose, so that, for example, the second dose may have to be adjusted to provide more of the drug than the first dose, to compensate for any competition between drug release and drug metabolism.
• the initial dose of methylphenidate drug in the dosage forms of the present invention can be provided by incorporating the methylphenidate drug into a form which allows for substantially immediate release of the drug once the dosage form is ingested by a patient.
• Such forms include, for example, powders, coated and uncoated pellets, and coated and uncoated tablets.
• the dose for immediate release can be administered in a tablet or capsule form which may also include the delayed dose.
• two or more groups of pellets may be combined within a hard gelatin capsule or compressed into a tablet.
• Powders can be granulated and can be combined with pellets and excipients and/or other additives, and contained within a capsule or compressed into a tablet.
• the delayed dose of a methylphenidate drug in the dosage forms of the present invention is provided in part by the use of certain copolymers referred to as "ammonio methacrylate copolymers".
• Ammonio methacrylate copolymers comprise acrylic and/or methacrylic ester groups together with quaternary ammonium groups. According to the present invention, the copolymers are incorporated into a formulation which is used to coat particles containing a medication.
• the "acrylic and/or methacrylic ester groups" in the copolymers used in the compositions and methods of the present invention are referred to herein collectively as "acrylic groups".
• the acrylic groups are preferably derived from monomers selected from C,-C 6 alkyl esters of acrylic acid and C,-C 6 alkyl esters of methacrylic acid. Preferred are C,-C 4 alkyl esters of acrylic acid and methacrylic acid. Suitable monomers include, for example, methyl acrylate, ethyl acrylate, methyl methacrylate, and ethyl methacrylate.
• Ethyl acrylate and methyl methacrylate are preferred, and copolymers containing ethyl acrylate and methyl methacrylate are highly preferred. Also preferably, the copolymers have a molecular weight of about 150,000.
• Quaternary ammonium groups in copolymers useful in forming coatings for use in the dosage forms of the present invention can be derived from monomers comprising quaternary ammonium groups.
• the monomers are alkyl esters of acrylic or methacrylic acid, comprising alkyl groups having from 1 to 6 carbon atoms and a quaternary ammonium group in the alkyl portion.
• Monomers comprising quaternary ammonium groups can be prepared, for example, by reaction of monomers containing amino groups with alkylating agents such as, for example, alkyl halides, especially methyl chloride.
• Suitable monomers containing amino groups include 2-(N,N-dibutylamino) ethyl acrylate, 2-(N,N-dibutylamino) ethyl methacrylate, 4-diethylamino-l -methyl-butyl acrylamide, and 4-diethylamino-l -methyl-butyl methacrylamide.
• Other useful monomers containing amino groups are disclosed in U.S. Patent No. 5,422,121, the disclosure of which is incorporated herein by reference.
• Particularly preferred as a monomer comprising a quaternary ammonium group is trimethylammonioethyl methacrylate chloride (TAMC1).
• ammonio methacrylate copolymers such as those described herein have been used for sustained delivery of certain medicaments, i.e., for the relatively constant administration of a drug
• dosage forms comprising a methylphenidate drug and a coating prepared from one or more ammonio methacrylate copolymers and certain fillers, can provide delayed or pulsatile release of the drug, a very distinct phenomenon.
• Methylphenidate drugs are amine- containing, rely upon body or membrane loading for efficacy, and are psychotropic.
• the ability to provide delayed release of a methylphenidate drags using ammonio methacrylate copolymers is due to a combination of factors, including the composition of the ammonio methacrylate copolymers used, and the amount and composition of filler.
• the ratio of acrylic groups to quaternary ammonium groups in the ammonio methacrylate copolymers influences the properties of the copolymers utilized in forming the coatings of the present invention.
• the ratio of acrylic groups to quaternary ammonium groups in the copolymers is preferably from about 10:1 to about 50:1, more preferably from about 15:1 to about 45: 1.
• two or more copolymers are used in combination.
• one of the copolymers comprises acrylic groups and quaternary ammonium groups in a ratio of from about 25 : 1 to about 45:1, more preferably from about 30:1 to about 40:1, and another of the copolymers comprises acrylic groups and quaternary ammonium groups in a ratio of from about 10: 1 to about 25 : 1 , more preferably from about 15 : 1 to about 20: 1.
• two ammonio methacrylate copolymers are used: a first copolymer comprising acrylic groups and quaternary ammonium groups in a ratio of from about 30: 1 to about 40: 1 and the second copolymer comprising acrylic groups and quaternary ammonium groups in a ratio of from about 15:1 to about 20: 1.
• the copolymers are copolymers of methyl methacrylate, ethyl acrylate, and TAMC1, in ratios of 2:1 :0.1 for the first copolymer and 2:1 :0.2 for the second copolymer.
• the relative amounts of the two polymers is partly determinative of the delay and release properties of the dosage forms of the present invention. It is preferred that the ratio between the first polymer, most preferably having an acrylic group/quaternary ammonium group ratio of from about 30:1 to about 40:1, and the second polymer, most preferably having an acrylic group/quaternary ammonium group ratio of from about 15:1 to about 20:1, be from about 93:7 to about 97:3. More preferably, the ratio of the first polymer to the second polymer is from about 96:4 to about 94:6, and most preferably about 95:5.
• Ammonio methacrylate copolymers used in the coatings of the dosage forms of the present invention can be prepared by methods known to those skilled in the art. Exemplary methods include emulsion polymerization, bulk polymerization and suspension polymerization. A suitable procedure is described in U.S. Patent No. 3,979,349, the disclosure of which is incorporated herein by reference. Suitable ammonio methacrylate copolymers are known per se, and can be purchased from commercial providers. For example, suitable ammonio methacrylate polymers are available from H ⁇ ls America under the Eudragit® trademarks. The Eudragit® polymers and similar polymers, including methods for preparation, are described in Klaus O. R. Lehman, "Chemistry and Application Properties of Polymethacrylate Coating Systems", Aqueous Polymeric
• the coatings of the present invention also preferably include a filler.
• the filler is preferably in powder form and is preferably hydrophobic.
• Exemplary fillers include talc, colloidal silica, fumed silica, gypsum, and glycerine monostearate. Talc is a particularly preferred filler.
• the quantity of filler used in preparing coatings for the dosage forms of the present invention should be sufficient to minimize agglomeration of the particles. Agglomeration is highly undesirable because the agglomerates, rather than discrete particles, will become coated. Agglomerates are susceptible to breaking into discrete particles, which will be partially uncoated, resulting in unwanted variability in release rates.
• the amount of filler is from about 30 percent to about 50 percent by weight, based on the total weight of the dry polymer, commonly referred to as "total solids". More preferably the amount of filler is from about 35 percent to about 45 percent of total solids, and most preferably about 40 percent.
• Coatings used in the dosage forms of the present invention also preferably include a material which improves the processing of the copolymers.
• plasticizers include, for example, citric acid esters, adipates, azelates, benzoates, citrates, stearates, isoebucates, sebacates, propanetriol acetate, polyethylene glycols, diethyl phthalate, dibutyl sebacate, propylene glycol and ethylene glycol.
• Citric acid esters are preferred, and triethyl citrate is particularly preferred.
• the amount of plasticizer to be used in the coating is preferably from about 10 percent to about 30 percent, more preferably from about 15 percent to about 25 percent, and most preferably about 20 percent, based on the weight of the dry polymer, i.e., total solids.
• Dosage forms of the present invention preferably comprise particles containing d-MPD.
• the dosage form comprises two groups of particles.
• a first group of particles provides the initial dose of d-MPD.
• the initial dose can be in powder, pellet or other particulate form and can be uncoated. If the initial dose is in the form of a powder or sufficiently small particles, it can, if desired, be pressed into a solid form such as a tablet or caplet.
• the delayed dose is provided by a second group of particles.
• the second group of particles is preferably in the form of pellets.
• the pellets can be of any shape, such as, for example, spheroids or ellipsoids, or may be irregularly shaped.
• Suitable pellets for the initial dose and/or the second dose can be formed by, for example, depositing a layer of drag, and optional excipients, carriers, and other optional materials, onto small, pharmaceutically acceptable particles such as nonpareils.
• a layer can be deposited by methods known to those skilled in the art, such as, for example, spraying, using methods and equipment known to those skilled in the art.
• spraying can also be accomplished using a pan coating system, wherein the drag is deposited by successive spraying accompanied by tumbling in a rotating pan.
• pellets can be formed, for either or both of the initial and delayed dose, by extrusion of the drag with suitable plasticizers and other processing aids as necessary.
• Tablets or caplets. or other solid dose forms comprising the initial dose and/or delayed dose or doses, can conveniently be administered.
• a solid dose form can be prepared by methods known to those skilled in the art.
• the d-MPO, filler and other optional components may be compressed into tablets or inserted into capsules.
• the drag and other components of the dose form can be granulated, using processing aids, fillers, aqueous or non-aqueous solvents, and binders known to those skilled in the art. Granules can be filled into capsules, if desired.
• the d- MPD can be blended with a solvent and processed by known methods such as ball-milling, calendering, stirring, or roll-milling, then pressed into a desired shape.
• Suitable solvents useful in forming the particles comprising ⁇ i-MPD, and other components of the dosage forms of the invention include inert organic and inorganic solvents which do not adversely affect the components of the dosage forms. While water can be used for many drugs, including methylphenidate, useful solvents can be selected from the group consisting of aqueous solvents, alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated solvents, cycloaliphatics, aromatic heterocyclic solvents, and mixtures thereof.
• solvents include acetone, methanol, ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate, isopropyl acetate, «-butyl acetate, methyl isobutyl ketone, methyl propyl ketone, «-hexane, H-heptane, ethylene glycol monoethyl ether, ethylene glycol monoethyl acetate, methylene dichloride. ethylene dichloride, propylene dichloride, nitroethane, nitropropane.
• tetrachloroethane diglyme
• aqueous and non- aqueous mixtures thereof such as acetone and water, acetone and methanol, acetone and ethyl alcohol, and ethylene dichloride and methanol.
• those particles to be used to deliver the delayed dose are then coated with a polymer-containing coating as described herein.
• the amount of coating to be used in forming the dosage forms, particularly the delayed dose, of the present invention will be determined by the desired delivery properties, including the amount of drug to be delivered, the delay time required, and the size of the particles.
• the coating on the particles providing the delayed dose including all solid components of the coating such as copolymer, filler, plasticizer and optional additives and processing aids, is from about 10 percent to about 60 percent, more preferably from about 20 percent to about 50 percent, most preferably from about 30 percent to about 40 percent, of the total final weight of the particles.
• the appropriate amount of coating can advantageously be determined using in vitro measurements of drug release rates obtained with selected amounts of coating.
• the coating can be deposited by any method known to those skilled in the art, such as spray application. Spraying can be carried out by pan coating or by use of a fluid bed, such as the Wurster fluid bed described for use in depositing a drug.
• a sealant can be applied to any and/or all of the particles, prior to application of the polymeric coating.
• a sealant provides a physical barrier between the drag and the coating, to minimize or prevent interaction between the drag and the coating.
• Suitable sealants can be prepared from materials such as biologically inert, permeable, pharmaceutically acceptable polymers, such as, for example, hydroxypropylalkylcelluloses, wherein "alkyl” refers to C,-C 6 hydrocarbon chains.
• Exemplary materials include hydroxypropyl methylcellulose, hydroxypropylethylcellulose, hydroxypropyl propylcellulose, and hydroxypropylbutylcellulose. Hydroxypropylmethylcellulose is preferred.
• sealants such as, for example, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, semipermeable polyurethanes, semipermeable sulfonated polystyrenes, semipermeable cross-linked polymers such as poly(vinylbenzyltrimethyl)ammonium chloride, these are not preferred as they may affect the release rate of certain drags including d-MPO.
• a sealant can be prepared by adding the material to water, and agitating for a time and at a rate sufficient to form a solution. The formation of a solution will be indicated, for example, by transparency and the absence of visually observable suspended material.
• the amount of material added to the water is not critical but is determined by viscosity. A solution which is too viscous will present difficulties in spraying. Generally, the amount of material should not exceed about 20 weight/volume percent, i.e., 20 g sealant material per 100 ml of water. Preferably, the amount of material in the water is from about 5 percent to about 15 weight/ volume percent, and more preferably about 10 weight/volume percent.
• the coated particles are cured. "Curing” means that the particles are held at a controlled temperature for a time sufficient to provide stable release rates. Stability in release rate is indicated when further curing does not affect the release rate. In contrast, instability of release rate means that as the cure time is increased, the release rate continues to vary. Curing for a sufficient time ensures that substantially the same release rate is obtained with all particles of a particular size coated with a given amount of a given coating composition.
• a suitable curing time can be determined by one of skill in the art without undue experimentation, by noting the variability in in vitro release times as curing time is varied. As a general guideline, many formulations can be cured in about 24 hours.
• Curing can be accomplished, for example, in a forced air oven. Curing can be carried out at any temperature above room temperature, "room temperature” being defined as from about 18 °C to about 25 °C. Preferably, curing is carried out at a temperature of from about 30 °C to about 50 °C, more preferably from about 35 °C to about 45 °C, and most preferably about 40 °C. Curing time can range from several hours to several days. Preferably, the coated particles are cured for at least about 24 hours, more preferably at least about 2 days, even more preferably at least about 3 days, still more preferably at least about 4 days, still even more preferably at least about 5 days, even more preferably at least about 6 days, and most preferably for about 7 days. While no significant adverse effects or advantages have been observed when the particles are cured for longer than about 7 days, it has been found that curing for less than about 24 hours may result in relatively poorer storage stability as compared to particles cured for longer periods of time.
• the amount of methylphenidate drag contained in the first and second groups of particles depends upon the prescribed dosage to be delivered to a patient.
• the first group of particles can consist substantially entirely of a methylphenidate drag. “Substantially entirely” means that about 95 percent or more of the weight of the first group of particles can consist of a methylphenidate drag.
• the first group of particles can also contain pharmaceutically acceptable carriers, excipients, and other components which do not interfere with the substantially immediate release of the medication. "Substantially immediate" release, as used herein, means that at least about 90 percent of the medication is released within about 30 minutes from the time the drug is ingested.
• the second group of particles can contain from about 2 percent to about 75 percent, preferably from about 4 percent to about 50 percent, medication, based on the total weight of the particles including the coating to be deposited thereon.
• a first and a second group of particles can be administered simultaneously as part of one dosage form.
• Any dosage form can be used.
• the two groups of particles can be combined within a capsule.
• the two groups of particles can be pressed into a solid form such as a tablet.
• suitable processing aids known to those skilled in the art can be used.
• particles coated to provide a delayed dose of a medication can be dispersed within or blended with, the medication in powder form.
• the dosage form can comprise a single group of particles providing both a substantially immediate dose of a methylphenidate drug, and a delayed dose of methylphenidate drag.
• the particles comprise, in admixture with one or more binders, from about 2% to about 75% by weight of a methylphenidate drug for delayed release, and a coating comprising the pharmaceutically acceptable, substantially neutral copolymers described herein.
• the particles further comprise, exterior to the coating, an outer layer comprising methylphenidate drag, to provide an initial, substantially immediate, dose.
• the substantially immediate dose is preferably released within about 30 minutes, more preferably about 15 minutes, and most preferably within about 5 minutes following ingestion.
• the outer layer can optionally comprise additives such as, for example, binders, excipients, and lubricants known to those skilled in the art.
• the dosage forms provided by the invention can be of any shape suitable for oral administration of a drag, such as spheroidal, cube-shaped, oval, bean shaped, or ellipsoidal.
• the dosage form may be in the form of granules, which may be irregularly shaped.
• the size of the particles is generally not critical, a certain particle size or sizes can be preferred depending upon the characteristics of the dosage form.
• the dosage form can comprise a capsule containing a first and/or second group of particles. The particles should then be of a size which allows for ease in handling, and which allows for the particles comprising a desired quantity of drag to be readily measured and inserted into the capsule.
• the particles are preferably of a size and shape which facilitate oral administration.
• the particles can be in the form of tablets, caplets. etc.
• the particles can be contained within a capsule of suitable size and shape for oral administration.
• various fillers and/or binders known to those skilled in the art can be included in the particles to provide the desired size and shape.
• the dosage forms of the present invention may include, in either or both of the first dose and any delayed dose, pharmaceutically acceptable carriers, extenders, fillers, processing aids, and excipients known to those skilled in the art.
• the following examples are merely illustrative of the present invention and should not be considered limiting of the scope of the invention in any way. These examples and equivalents thereof will become more apparent to those skilled in the art in light of the present disclosure and the accompanying claims.
• Example 1 Preparation of layered pellets containing ⁇ -MPD hydrochloride A solution of -MPD hydrochloride was prepared as follows. To 300 grams (g) of deionized water were added 100 g of d-MPO hydrochloride, followed by moderate mixing, using a stirring paddle, for 5 minutes. A 10 percent (weight) solution of hydroxypropyl methylcellulose (HPMC E-6 from Dow Chemicals, Midland, MI; 250 g) was added, followed by homogenization for 5 minutes using an emulsifier head (Silverson, Chesham, UK; Model L4R). After addition of another 150 g of deionized water, the solution was sonicated for 15 minutes (Sonicor Model SC-150T; Instraments Corporation, Copiague, NY), at which time the solution was clear.
• HPMC E-6 hydroxypropyl methylcellulose
• a second solution was prepared by combining 300 g of deionized water and 300 g of a 10% (wt) HPMC E-6 solution and mixing for 5 minutes. The first solution was sprayed onto 25/30 mesh non-pareil seeds (Ozone
• a dispersion of 844 g of Eudragit® RS30D (ammoniomethacrylate copolymer from H ⁇ ls America, Somerset, NJ; EA/MMA/TAMC1 1:2:0.1), was screened through a 60 mesh screen, then stirred for 15 minutes.
• a dispersion of 44 g of Eudragit® RL30D (EA/MMA/TAMCl 1 :2:0.2) was similarly screened and stirred. The two dispersions were combined and stirred for 15 minutes, forming a combined dispersion.
• Triethyl citrate (TEC; from Moreflex, Greensboro, NC; 54 g) was added, followed by an additional 15 minutes of stirring.
• Deionized water (664 g) was added, followed by 15 minutes of stirring.
• Talc (108 g; from Luzenac, Englewood, CO) was added, followed by further stirring for 15 minutes.
• Example 2 The resulting combined dispersion was sprayed onto layered pellets prepared according to Example 1 , using a fluid bed apparatus as used in Example 1. Spray rate was 9-10 g/minute, inlet temperature 40-45 °C, and air volume 5-6 m/s. The nonpareils were maintained at 30-35 °C during spraying. A total of 960 g of dispersion was sprayed onto the pellets, representing a 30% weight increase due to the applied coating.
• Example 3 Evaluation of drag release profile for coated pellets prepared according to Example 2
• Pellets were prepared according to Example 2, varying the ratios of the polymers between 90:10 and 93:7. Dissolution measurements
• Dissolution was carried out in order to determine rate of release of d-MPO from the pellets.
• USP Apparatus I United States Pharmacoepia Convention, Rockville, MD
• the dissolution medium was 900 ml of deionized water (unless otherwise specified) and the temperature was maintained at 37 °C.
• the sample cell size was 1 cm (a flow through cell), and the samples were stirred continuously at 100 rpm.
• the apparatus was equipped with a diode array spectrophotometer, and absorption at 220 nanometers (nanometers (nm)) was measured to determine the concentration of d-MPO.
• a dispersion of 911.25 g of Eudragit® RS30D was passed through a 60 mesh screen and mixed with a similarly screened dispersion of 101.25 g of Eudragit® RL30D for 15 minutes at moderate speed.
• Triethyl citrate (61 g) was added, followed by an additional 15 minutes of mixing. After mixing, 991.5 g of deionized water, then 61 g of talc were added with 15 additional minutes of mixing following each addition.
• the resulting dispersion (1600 g) was sprayed onto 800 g of layered sealed pellets prepared according to Example 1.
• a dispersion of 600 g of Eudragit® NE30D was screened through a 60 mesh screen and mixed with a 600 g dispersion of magnesium stearate for 15 minutes at moderate speed.
• the resulting dispersion (750 g) was sprayed onto 750 g of layered and sealed pellets prepared according to Example 1.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Analytical Chemistry (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25399524

Family Applications (1)

Country Status (11)

Cited By (21)

Families Citing this family (229)

Citations (4)

Family Cites Families (95)

• 1997
  • 1997-07-14 US US08/892,190 patent/US5837284A/en not_active Expired - Lifetime
• 1998
  • 1998-03-11 US US09/038,470 patent/US6635284B2/en not_active Expired - Lifetime
  • 1998-06-09 DE DE69831869T patent/DE69831869T2/de not_active Expired - Lifetime
  • 1998-06-09 AU AU78343/98A patent/AU738744B2/en not_active Expired
  • 1998-06-09 AT AT98926529T patent/ATE306266T1/de active
  • 1998-06-09 EP EP98926529A patent/EP1001772B1/en not_active Expired - Lifetime
  • 1998-06-09 WO PCT/US1998/012057 patent/WO1999003471A1/en not_active Ceased
  • 1998-06-09 DE DE1001772T patent/DE1001772T1/de active Pending
  • 1998-06-09 EP EP05075103A patent/EP1541147A1/en not_active Withdrawn
  • 1998-06-09 DK DK98926529T patent/DK1001772T3/da active
  • 1998-06-09 ES ES98926529T patent/ES2153338T3/es not_active Expired - Lifetime
  • 1998-06-09 JP JP50716699A patent/JP2002510318A/ja not_active Withdrawn
  • 1998-06-09 EP EP05076618A patent/EP1607093A1/en not_active Withdrawn
  • 1998-06-11 CA CA002240329A patent/CA2240329C/en not_active Expired - Lifetime
• 2003
  • 2003-06-10 US US10/458,451 patent/US7431944B2/en not_active Expired - Fee Related
• 2005
  • 2005-10-25 HK HK05109482A patent/HK1077501A1/en unknown
• 2010
  • 2010-07-09 JP JP2010157017A patent/JP5412700B2/ja not_active Expired - Fee Related

Patent Citations (4)

Also Published As

Similar Documents

Legal Events